Myeloproliferative Neoplasms Treatment Market Analysis, Consumer Distribution, Companies List,

24/mag/2019 13:12:53 Healthcare Market Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.
Myeloproliferative Neoplasms (MPNs) are a group of rare diseases, in which the bone marrow produces excess blood cells. It can be white blood cells, red blood cells or platelets. The overproduction of blood cells by the bone marrow creates hindrance in the smooth flow of blood, which leads to various symptoms such as progressive cytopenias, cachexia and weight loss, splenomegaly, and blastic transformation. These conditions are developed gradually over a period of time. Most people are diagnosed after the age of 60 years, makes the treatment more difficult.
The major symptoms associated with MPNs include bleeding problem, anemia, chest pain, fatigue, enlarged spleen, and weight loss. According to Annals of Hematology, approximately 90% of patients have experienced MPN-symptoms in past 12 months, where women are reported to have higher overall burden than men. The treatment for myeloproliferative neoplasms is mainly aimed at reducing the excess number of blood cells circulation. The concept of myleoproliferative disease was first given by hematologist Williom Dameshek in 1950.
Request For a Sample Copy of This Research Report:  
Rising awareness of molecular abnormalities and myeloproliferative neoplasms treatment market growth in the near future
Myeloproliferative neoplasm can significantly affect the quality of life of the patient. Complications and treatments as well as physiological strains of cancer diagnosis and physical wellbeing of patients. Effects of complication vary from depression, fatigue, pain or depression with suicidal ideation. Moreover, patients may experience few or no symptoms for a longer period of time. MPNs can be cured with proper monitoring and treatment. There has been a major revolution in the management of MPNs by introduction of JAK1 and JAK2 inhibitor and ruxolitinib. Ruxolitinib inhibits these two enzymes in order to manage MPNs. The drug has also been shown to be an alternative therapy for the treatment of polycythemia vera. Further, the therapeutic armamentarium for MPN is still inadequate for normalization of life span,
Rising awareness of molecular abnormalities and cell pathways involve in the pathogenesis of MPNs is facilitated in the development of clinical trials with novel drugs, either alone or in combination with ruxolitinib. Interferon (IFN) is a drug that has proven to be an effective alternative for MPNs patients. It could lead to better interferon compound and potential drugs. In 2017, MPN research foundation have initiated MPNRF Interferon (IFN) multi-center project which is expected to bring together internationally recognized experts to determine cytokine-driven pathways that affect the path of the MPNs. It is a closely-related group of progressive blood cancer in the Myeloproliferative Neoplasms treatment market.
Collaboration among the biotech and pharmaceutical companies to identify new drugs for MPNs is expected to accelerate the market growth
Novartis AG and Incyte Corporation are among the key players in Myeloproliferative Neoplasms treatment market. According to MPN research foundation, biotech and pharmaceutical companies are expected to offer better treatments and quickly connecting patients with latest treatment options. It is designed to develop relationships with scientific and pharmaceutical companies to identify new areas for scientific exploration. For instance, Incyte Corporation is developing inhibitors for Janus Kinase (JAK) and also focusing on the discovery, development, and commercialization of proprietary therapeutics globally.
Click To Read More On Myeloproliferative Neoplasms Treatment Market  
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and the potential absolute dollar opportunity.
blog comments powered by Disqus è un servizio offerto da Factotum Srl